These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26716930)

  • 1. Long-Term Remissions in Recalcitrant Pemphigus Vulgaris.
    Ahmed AR; Kaveri S; Spigelman Z
    N Engl J Med; 2015 Dec; 373(27):2693-4. PubMed ID: 26716930
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical resolution of pemphigus vulgaris on rituximab.
    Cusick E; Silverstein D
    Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
    Brown AE; Motaparthi K; Hsu S
    Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for pemphigus vulgaris.
    Joly P; D'Incan M; Musette P
    N Engl J Med; 2007 Feb; 356(5):521; author reply 521-2. PubMed ID: 17267915
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of the Effects of Rituximab Monotherapy on Different Subsets of Circulating T-Regulatory Cells and Clinical Disease Severity in Severe Pemphigus Vulgaris.
    Bhattacharjee R; De D; Handa S; Minz RW; Saikia B; Joshi N
    Dermatology; 2016; 232(5):572-577. PubMed ID: 27576321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recalcitrant pemphigus vulgaris: aseptic meningitis associated with intravenous immunoglobulin therapy and successful treatment with rituximab.
    Ventura F; Rocha J; Fernandes JC; Machado A; Brito C
    Int J Dermatol; 2013 Apr; 52(4):501-2. PubMed ID: 23451774
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
    Feldman RJ; Christen WG; Ahmed AR
    Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-desmoglein antibody-negative paraneoplastic pemphigus successfully treated with rituximab.
    Kanwar AJ; Vinay K; Varma S; Koga H; Ishii N; Hashimoto T
    Int J Dermatol; 2015; 54(5):576-9. PubMed ID: 24738571
    [No Abstract]   [Full Text] [Related]  

  • 10. Is it time to re-evaluate the treatment of pemphigus?
    Leventhal JS; Sanchez MR
    J Drugs Dermatol; 2012 Oct; 11(10):1200-6. PubMed ID: 23134985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete remission after rituximab therapy in an HIV-positive patient with pemphigus vulgaris.
    Polansky M; Patel N; Feldman R
    Br J Dermatol; 2015 Dec; 173(6):1557-9. PubMed ID: 26122850
    [No Abstract]   [Full Text] [Related]  

  • 12. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
    Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
    Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
    El Tal AK; Posner MR; Spigelman Z; Ahmed AR
    J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolution of a case of pediatric pemphigus vulgaris treated with rituximab.
    Didona D; Paolino G; Donati M; Caposeina D; Calvieri S; Didona B
    Acta Dermatovenerol Croat; 2014; 22(4):288-90. PubMed ID: 25580789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients.
    Matsukura S; Knowles SR; Walsh S; Shear NH
    Arch Dermatol; 2012 Jun; 148(6):734-9. PubMed ID: 22351790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab.
    Schmidt E; Herzog S; Bröcker EB; Zillikens D; Goebeler M
    Br J Dermatol; 2005 Aug; 153(2):449-51. PubMed ID: 16086770
    [No Abstract]   [Full Text] [Related]  

  • 17. [[Treatment of therapy resistant pemphigus vulgaris with rituximab and immunoglobulins].
    Mühlhoff C; Megahed M
    Hautarzt; 2007 Nov; 58(11):924-6. PubMed ID: 17952393
    [No Abstract]   [Full Text] [Related]  

  • 18. [Rituximab induced remission of pemphigus vulgaris: 2 cases].
    Borel C; Launay F; Garrouste C; Astudillo L; Bazex J; Arlet P; Paul C; Viraben R; Sailler L
    Rev Med Interne; 2007 Apr; 28(4):266-8. PubMed ID: 17188405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-lasting remission of pemphigus vulgaris treated with rituximab.
    Esposito M; Capriotti E; Giunta A; Bianchi L; Chimenti S
    Acta Derm Venereol; 2006; 86(1):87-9. PubMed ID: 16586007
    [No Abstract]   [Full Text] [Related]  

  • 20. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: Treatment with cyclosporin in addition to steroid, rituximab and intravenous immunoglobulin.
    Namba C; Tohyama M; Hanakawa Y; Murakami M; Shirakata Y; Matsumoto T; Suemori K; Ishii N; Hashimoto T; Sayama K
    J Dermatol; 2016 Apr; 43(4):419-22. PubMed ID: 26506947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.